Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities

por Sanjiv, Kumar, Hagenkort, Anna, Calderón-Montaño, José Manuel, Koolmeister, Tobias, Reaper, Philip M., Mortusewicz, Oliver, Jacques, Sylvain A., Kuiper, Raoul V., Schultz, Niklas, Scobie, Martin, Charlton, Peter A., Pollard, John R., Berglund, Ulrika Warpman, Altun, Mikael, Helleday, Thomas
Publicado 2015

Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities

por Sanjiv, Kumar, Hagenkort, Anna, Calderón-Montaño, José Manuel, Koolmeister, Tobias, Reaper, Philip M., Mortusewicz, Oliver, Jacques, Sylvain A., Kuiper, Raoul V., Schultz, Niklas, Scobie, Martin, Charlton, Peter A., Pollard, John R., Berglund, Ulrika Warpman, Altun, Mikael, Helleday, Thomas
Publicado 2016

Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970

por Hall, Amy B., Newsome, Dave, Wang, Yuxin, Boucher, Diane M., Eustace, Brenda, Gu, Yong, Hare, Brian, Johnson, Mac A., Milton, Sean, Murphy, Cheryl E., Takemoto, Darin, Tolman, Crystal, Wood, Mark, Charlton, Peter, Charrier, Jean-Damien, Furey, Brinley, Golec, Julian, Reaper, Philip M., Pollard, John R.
Publicado 2014

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A

por Williamson, Chris T., Miller, Rowan, Pemberton, Helen N., Jones, Samuel E., Campbell, James, Konde, Asha, Badham, Nicholas, Rafiq, Rumana, Brough, Rachel, Gulati, Aditi, Ryan, Colm J., Francis, Jeff, Vermulen, Peter B., Reynolds, Andrew R., Reaper, Philip M., Pollard, John R., Ashworth, Alan, Lord, Christopher J.
Publicado 2016